Trade now with Barclays Stockbrokers
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£21,449,758 |
Nicolas Loebel |
3,538,991 |
£485,628 |
Junaid Bajwa |
1,193,697 |
£163,802 |
Jean Duvall |
1,163,529 |
£159,662 |
Jean Charest |
353,356 |
£48,488 |
Simon Sinclair |
256,327 |
£35,174 |
Carolyn Cross |
118,091,377 |
£16,204,761 |
M&G Plc |
40,588,235 |
£5,569,608 |
Robert Cross |
25,858,400 |
£3,548,347 |
Albemarle Life Sciences Fund |
15,105,882 |
£2,072,863 |
CRUX Asset Management |
9,298,090 |
£1,275,905 |
Chelverton Asset Management |
7,957,311 |
£1,091,920 |
09:42 |
714 @ 14.00p |
08:31 |
74,044 @ 13.50p |
08:12 |
60,606 @ 13.19p |
09:01 |
10,000 @ 13.18p |
08:33 |
20,000 @ 13.48p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research